Stemberger-Papić Snjezana, Vrdoljak-Mozetic Danijela, Ostojić Damjana Versa, Rubesa-Mihaljević Roberta, Krigtofić Ines, Brncić-Fisher Alemka, Kragević Maja, Eminović Senija
Coll Antropol. 2015 Sep;39(3):745-53.
The cancer stem cells (CSCs) represent a minority of tumor cells that are able to proliferate and self-renew and might be responsible for tumor initiation and maintenance. The CD133 and CD117 are the most commonly used markers for the putative CSCs, especially for the ovarian CSCs, but its clinical significance remains uncertain. The aim of this study was to compare the immunohistochemical expression of CD133 and CD117 in 64 primary ovarian high grade serous carcinoma and peritoneal metastasis, and to examine their potential clinical role. CD133 expression was mainly seen in the apical/endoluminal cell surface of tumor cells and was found in 61% of the carcinoma samples and 41% of the metastasis. The median of CD133 positive cells in tumors was 1 (0.1-7)%, and in metastases was 0.6 (0.1-6)%. CD117 expression appeared as a cytoplasmic and/or membranous stain and was found in 81% of the carcinoma samples and 77% of the metastasis. The median of CD117 positive cells in tumors was 1 (0.1-8)%, and in metastases was 0.1 (0.1-7)%. Multivariate analysis has shown that patients with high CD133 expression in tumor cells have significantly shorter disease free survival and overall survival (p=0.025 and p=0.014, respectively). Patients with high CD117 expression in tumor cells have significantly shorter disease free survival (p=0.031). Cox's proportional hazards model identified expression of CD133 protein in tumor as an independent prognostic factor. Our study indicates that the immunohistochemical assessment of CD133 and CD117 expression may have potential clinical value in predicting disease progression and prognosis in the high grade serous ovarian cancer. CD133 proved to be an independent prognostic factor in the high grade serous ovarian cancer patients.
癌症干细胞（CSCs）是少数能够增殖和自我更新的肿瘤细胞，可能与肿瘤的起始和维持有关。CD133和CD117是最常用于推定的癌症干细胞的标志物，尤其是卵巢癌干细胞，但它们的临床意义仍不明确。本研究的目的是比较64例原发性卵巢高级别浆液性癌及其腹膜转移灶中CD133和CD117的免疫组化表达情况，并探讨它们潜在的临床作用。CD133表达主要见于肿瘤细胞的顶端/腔内细胞表面，在61%的癌组织样本和41%的转移灶中被发现。肿瘤中CD133阳性细胞的中位数为1（0.1 - 7）%，转移灶中为0.6（0.1 - 6）%。CD117表达表现为细胞质和/或膜染色，在81%的癌组织样本和77%的转移灶中被发现。肿瘤中CD117阳性细胞的中位数为1（0.1 - 8）%，转移灶中为0.1（0.1 - 7）%。多变量分析表明，肿瘤细胞中CD133高表达的患者无病生存期和总生存期显著缩短（分别为p = 0.025和p = 0.014）。肿瘤细胞中CD117高表达的患者无病生存期显著缩短（p = 0.031）。Cox比例风险模型确定肿瘤中CD133蛋白的表达是一个独立的预后因素。我们的研究表明，CD133和CD117表达的免疫组化评估在预测高级别浆液性卵巢癌的疾病进展和预后方面可能具有潜在的临床价值。CD133被证明是高级别浆液性卵巢癌患者的一个独立预后因素。
